ELISpot/FluoroSpot 检测的全球市场：市场规模和占有率分析（依产品类型、应用和最终用户）、工业需求预测（截至 2030 年）

预计 2023 年全球 ELISpot/FluoroSpot 检测市场规模将达到 2.895 亿美元，2024 年至 2030 年复合年增长率为 7.9%，到 2030 年将达到 4.908 亿美元。

检测试剂盒占比最大

由于传染病和慢性病的流行以及检测试剂盒的相关开发，检测试剂盒可能会在本十年末引领市场。

ELISpot 检测用于检查疫苗针对干扰素、发炎介质和白血球介素等免疫介质的效率。 此外，此测定的主要优点是成本效益高且结果显示迅速。

医院和诊所是主要的最终使用者

2023 年，医院和诊所的市占率最大，达 60%。 这是因为许多患者首选医院和诊所进行疾病诊断，特别是在新兴国家。

北美是市场领导者

到 2023 年，北美将占据 55% 的占有率，成为依地区划分的最大市场。 根据美国人口普查局的数据，美国约有 5,600 万 65 岁及以上的成年人，约占全国总人口的 16.9%。

中国引领亚太市场

在亚太地区，中国将成为成长最快的市场。 这主要是由于癌症和其他慢性疾病的流行、对研发活动的日益重视、患者数量的增加以及医疗保健支出的迅速增加。

在本报告中，我们分析了全球 ELISpot/FluoroSpot 检测市场，包括市场的基本结构和最新情况、主要促进和抑制因素以及全球、依地区和主要国家的市场规模前景（金额（2017-2030 ），依产品类型、应用和最终用户划分的详细趋势、市场竞争现状以及主要公司概况。

目录

第一章研究范围

第二章研究方法

第 3 章执行摘要

第 4 章市场指标

第五章产业展望

• 市场动态
  • 趋势
  • 促进因素
  • 抑制因素/课题
  • 促进/抑制因子影响分析
• 新型冠状病毒感染 (COVID-19) 的影响
• 波特五力分析

第六章世界市场

• 摘要
• 市场收入：依产品类型划分（2017-2030 年）
• 市场收入：依应用分类（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）
• 市场收入：依地区划分（2017-2030 年）

第七章北美市场

• 摘要
• 市场收入：依产品类型划分（2017-2030 年）
• 市场收入：依应用分类（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）
• 市场收入：依国家/地区划分（2017-2030 年）

第8章欧洲市场

第9章亚太市场

第10章拉丁美洲市场

第 11 章中东与非洲 (MEA) 市场

第12章美国市场

• 摘要
• 市场收入：依产品类型划分（2017-2030 年）
• 市场收入：依应用分类（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）

第十三章加拿大市场

第14章德国市场

第十五章法国市场

第十六章英国市场

第十七章义大利市场

第十八章西班牙市场

第十九章日本市场

第20章中国市场

第21章印度市场

第22章澳洲市场

第23章韩国市场

第24章巴西市场

第25章墨西哥市场

第26章沙乌地阿拉伯市场

第27章南非市场

第 28 章阿联酋 (UAE) 市场

第29章竞争态势

• 市场参与者及其提供的产品/服务的列表
• 主要公司的竞争基准
• 各大公司的产品基准
• 近期策略发展状况

第30章公司简介

• Oxford Immunotec
• Cellular Technology Limited
• Mabtech AB
• Becton, Dickinson and Company
• Bio-Techne Corporation

第31章附录

The value of the ELISpot and FluoroSpot assay market was USD 289.5 million in 2023, and it will power at a compound annual growth rate of 7.9% during 2024-2030, to touch USD 490.8 million by 2030.

Market Drivers

Some driving factors of the industry are the growing occurrence of infectious and chronic diseases at a global level, particularly HIV, and the growing elderly population.

ELISpot and FluoroSpot are performed for several diseases, for instance, cancer, infectious diseases, and, autoimmune ailments. The ELISpot assay clearly spots the number of cytokine-secreting cell with high specialty and sensitivity.

These benefits make it an effective tool for measuring the degree of adaptive and innate immune responses.

As stated by the CDC's NCEZID, the infectious disease risk is increasing incessantly due to the change in climate all over the world.

Lyme disease, Valley fever, and West Nile disease are some infectious diseases, rising in prevalence and spreading to novel regions of the U.S. This is because of the warmer summers, milder winters, and fewer days with frost.

Assay Kits Hold Largest Share

Assay kits will lead the market by the end of this decade because of the growing incidence of infectious and chronic ailments, accompanied by the development in assay kits.

The ELISpot assay is used to examine the vaccine efficiency on immune mediators, for example, interferons, pro-inflammatory mediators, and interleukins. Additionally, the main benefit of this assay is that it is cost-effective and displays results quickly.

Hospitals and Clinics are the Major End Users

Hospitals and clinics were the leaders of the market, with a share of 60%, in 2023. This is because hospitals and clinics and preferred by most patients for disease diagnosis, particularly in emerging countries.

Furthermore, with continued efforts of the government, the count of such medical centers is on the rise, at a global level, which drives the demand for all sorts of therapeutic and diagnostic equipment at these places.

For addressing the huge demand for biopharmaceuticals, there is a growing emphasis on research and, related spending. The capability of biopharmaceuticals for treating ailments that were incurable before has brought about the release of these kinds of new medications in the market.

Therefore, the market under investigation will grow by the end of this decade.

North America is the Leader of the Market

North America was the regional leader of the market, with a 55% share, in 2023. As per the U.S. Census Bureau, approximately 56 million adults aged 65 or more are in the U.S. and make about 16.9% of the total population of the country.

Further, there will be over 73 million older adults by the time 2030 comes to an end, which means over 20% of people will be older. The total count of adults aged 65 and more will increase to 85.7 million by 2050 and will comprise 22% of the total population of the nation.

China Leads the Pack in the APAC Market

In the APAC region, China will be the fastest-growing market. This has a lot to do with the prevalence of cancer and other chronic ailments, increasing emphasis on research and development activities, rising patient populace, and surging healthcare spending.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by product type
  • 1.4.2. Market size breakdown, by application
  • 1.4.3. Market size breakdown, by end user
  • 1.4.4. Market size breakdown, by region
  • 1.4.5. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Product Type (2017-2030)
• 6.3. Market Revenue, by Application (2017-2030)
• 6.4. Market Revenue, by End User (2017-2030)
• 6.5. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Product Type (2017-2030)
• 7.3. Market Revenue, by Application (2017-2030)
• 7.4. Market Revenue, by End User (2017-2030)
• 7.5. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Product Type (2017-2030)
• 8.3. Market Revenue, by Application (2017-2030)
• 8.4. Market Revenue, by End User (2017-2030)
• 8.5. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Product Type (2017-2030)
• 9.3. Market Revenue, by Application (2017-2030)
• 9.4. Market Revenue, by End User (2017-2030)
• 9.5. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Product Type (2017-2030)
• 10.3. Market Revenue, by Application (2017-2030)
• 10.4. Market Revenue, by End User (2017-2030)
• 10.5. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Product Type (2017-2030)
• 11.3. Market Revenue, by Application (2017-2030)
• 11.4. Market Revenue, by End User (2017-2030)
• 11.5. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Product Type (2017-2030)
• 12.3. Market Revenue, by Application (2017-2030)
• 12.4. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Product Type (2017-2030)
• 13.3. Market Revenue, by Application (2017-2030)
• 13.4. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Product Type (2017-2030)
• 14.3. Market Revenue, by Application (2017-2030)
• 14.4. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Product Type (2017-2030)
• 15.3. Market Revenue, by Application (2017-2030)
• 15.4. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Product Type (2017-2030)
• 16.3. Market Revenue, by Application (2017-2030)
• 16.4. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Product Type (2017-2030)
• 17.3. Market Revenue, by Application (2017-2030)
• 17.4. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Product Type (2017-2030)
• 18.3. Market Revenue, by Application (2017-2030)
• 18.4. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Product Type (2017-2030)
• 19.3. Market Revenue, by Application (2017-2030)
• 19.4. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Product Type (2017-2030)
• 20.3. Market Revenue, by Application (2017-2030)
• 20.4. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Product Type (2017-2030)
• 21.3. Market Revenue, by Application (2017-2030)
• 21.4. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Product Type (2017-2030)
• 22.3. Market Revenue, by Application (2017-2030)
• 22.4. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Product Type (2017-2030)
• 23.3. Market Revenue, by Application (2017-2030)
• 23.4. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Product Type (2017-2030)
• 24.3. Market Revenue, by Application (2017-2030)
• 24.4. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Product Type (2017-2030)
• 25.3. Market Revenue, by Application (2017-2030)
• 25.4. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Product Type (2017-2030)
• 26.3. Market Revenue, by Application (2017-2030)
• 26.4. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Product Type (2017-2030)
• 27.3. Market Revenue, by Application (2017-2030)
• 27.4. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Product Type (2017-2030)
• 28.3. Market Revenue, by Application (2017-2030)
• 28.4. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Oxford Immunotec
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. Cellular Technology Limited
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Mabtech AB
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Becton, Dickinson and Company
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Bio-Techne Corporation
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports